KR20110031980A - 호지킨병의 치료를 위한 ｈｄａｃ 억제제의 용도 - Google Patents

호지킨병의 치료를 위한 ｈｄａｃ 억제제의 용도 Download PDF

Info

Publication number
KR20110031980A
KR20110031980A KR1020117003661A KR20117003661A KR20110031980A KR 20110031980 A KR20110031980 A KR 20110031980A KR 1020117003661 A KR1020117003661 A KR 1020117003661A KR 20117003661 A KR20117003661 A KR 20117003661A KR 20110031980 A KR20110031980 A KR 20110031980A
Authority
KR
South Korea
Prior art keywords
alkyl
aryl
heteroaryl
heterocycloalkyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020117003661A
Other languages
English (en)
Korean (ko)
Inventor
피터 위즈덤 아타쟈
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20110031980A publication Critical patent/KR20110031980A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020117003661A 2008-07-18 2009-07-16 호지킨병의 치료를 위한 ｈｄａｃ 억제제의 용도 Withdrawn KR20110031980A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8180508P 2008-07-18 2008-07-18
US61/081,805 2008-07-18

Publications (1)

Publication Number Publication Date
KR20110031980A true KR20110031980A (ko) 2011-03-29

Family

ID=41128203

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117003661A Withdrawn KR20110031980A (ko) 2008-07-18 2009-07-16 호지킨병의 치료를 위한 ｈｄａｃ 억제제의 용도

Country Status (15)

Country Link
US (1) US20110118309A1 (enExample)
EP (1) EP2306996A1 (enExample)
JP (1) JP2011528662A (enExample)
KR (1) KR20110031980A (enExample)
CN (1) CN102099021A (enExample)
AU (1) AU2009270886A1 (enExample)
BR (1) BRPI0915927A2 (enExample)
CA (1) CA2730738A1 (enExample)
CL (1) CL2011000100A1 (enExample)
IL (1) IL210489A0 (enExample)
MA (1) MA32482B1 (enExample)
MX (1) MX2011000719A (enExample)
TW (1) TW201006470A (enExample)
WO (1) WO2010009280A1 (enExample)
ZA (1) ZA201100165B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102020939B1 (ko) * 2011-07-07 2019-09-11 리서치 캔서 인스티튜트 오브 아메리카 암 치료 시스템, 방법 및 제형
US8933078B2 (en) 2011-07-14 2015-01-13 Research Cancer Institute Of America Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances
WO2018157081A1 (en) 2017-02-27 2018-08-30 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
US11369585B2 (en) 2017-03-17 2022-06-28 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
CN109705057B (zh) * 2017-10-25 2023-05-30 成都先导药物开发股份有限公司 组蛋白去乙酰化酶抑制剂及其制备方法与用途
EP3710434A4 (en) 2017-11-17 2021-07-28 Research Cancer Institute of America COMPOSITIONS, METHODS, SYSTEMS AND / OR KITS FOR THE PREVENTION AND / OR TREATMENT OF NEOPLASMS
US20220387604A1 (en) * 2019-11-06 2022-12-08 Dana-Farber Cancer Institute, Inc. Selective dual histone deacetylase 6/8 (hdac6/8) degraders and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
JP2009541488A (ja) * 2006-06-26 2009-11-26 ノバルティス アクチエンゲゼルシャフト 有機化合物
US8093220B2 (en) * 2006-12-04 2012-01-10 Novartis Ag Combination of an HDAC inhibitor and an antimetabolite

Also Published As

Publication number Publication date
CN102099021A (zh) 2011-06-15
CL2011000100A1 (es) 2011-07-01
JP2011528662A (ja) 2011-11-24
WO2010009280A1 (en) 2010-01-21
AU2009270886A1 (en) 2010-01-21
TW201006470A (en) 2010-02-16
ZA201100165B (en) 2011-09-28
US20110118309A1 (en) 2011-05-19
MX2011000719A (es) 2011-03-01
IL210489A0 (en) 2011-03-31
EP2306996A1 (en) 2011-04-13
MA32482B1 (fr) 2011-07-03
BRPI0915927A2 (pt) 2016-06-07
CA2730738A1 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
KR101561750B1 (ko) Ｍｄｍ2/4 및 ｐ53 상호작용의 억제제의 결정질 형태
EP2721007B1 (en) Cyclohexyl isoquinolinone compounds
KR20090073121A (ko) Ｐｉ3ｋ 지질 키나제 억제제로서의 피라졸로피리미딘
KR20110031980A (ko) 호지킨병의 치료를 위한 ｈｄａｃ 억제제의 용도
AU2017251741A1 (en) Combination products with tyrosine kinase inhibitors and their use
AU2009257487B2 (en) Substituted benzimidazoles for neurofibromatosis
EP3174869A1 (en) Combination therapy
KR20140034898A (ko) 헤테로시클릭 술폰아미드 유도체
WO2010009285A1 (en) Use of hdac inhibitors for the treatment of acute myeloid leukemia and/or myelodysplastic syndrome
JP2012516345A (ja) 星細胞腫治療用置換ベンゾイミダゾール
HK40064964A (en) Combination products with tyrosine kinase inhibitors and their use
HK1184091B (en) Crystalline form of an inhibitor of mdm2/4 and p53 interaction

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20110217

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid